title: Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
abstract: BACKGROUND
  The most frequently used therapy for post-transplantation recurrence of hepatitis B virus (HBV) infection is lamivudine, but this drug is associated with a high resistance rate due to YMDD mutant. In preliminary reports, adefovir dipivoxil (ADV) has been shown to have activity against lamivudine-resistant strains of HBV. However, clinical experience in treatment of HBV infection after liver transplantation (LT) is still not entirely clear. This study was aimed to evaluate the prophylactic efficacy of ADV plus hepatitis B immunoglobulin (HBIG) in patients with YMDD mutant before LT.
  
  
  METHODS
  From March 2004 to March 2006, 16 patients with chronic hepatitis B had lamivudine-resistant YMDD mutants detected prior to liver transplantation and received treatment with ADV plus additional intramuscular HBIG after LT as prophylaxis against graft reinfection. Tests for liver function, serum HBsAg, anti-HBs (HBIG), HBeAg, anti-HBc, anti-HBe, HBV-DNA, and creatinine were assessed pre- or post-liver transplantation.
  
  
  RESULTS
  The median follow-up of these patients post-liver transplantation was 19.4 months. Fifteen patients survived and one patient died of recurrence of hepatocellular carcinoma (HCC). There was significant difference (10.98% vs. 2.26%, P < 0.05) in YMDD mutant rate between the patients with HBV-DNA over 10(6) copies/ml and those with HBV-DNA less than 10(6) copies/ml. Fifteen patients (93.8%) had undetectable HBV-DNA at 4 weeks and 1 (6.3%) at 6 months after LT. No hepatitis B recurrence was detected by persistent testing of HBsAg, HBeAg, and HBV-DNA and no increase of serum creatinine level associated with ADV was observed in any of the patients.
  
  
  CONCLUSIONS
  ADV combined with intramuscular HBIG can effectively prevent patients with pre-transplantation YMDD mutant from HBV recurrence after LT.
authors.affiliation: Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.forename: Chang-jie
authors.initials: CJ
authors.lastname: Cai
authors.forename: Ming-qiang
authors.initials: MQ
authors.lastname: Lu
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.forename: Nan
authors.initials: N
authors.lastname: Jiang
authors.forename: Hua
authors.initials: H
authors.lastname: Jiang
authors.forename: Chi
authors.initials: C
authors.lastname: Xu
authors.forename: Hua
authors.initials: H
authors.lastname: Li
authors.forename: Gen-shu
authors.initials: GS
authors.lastname: Wang
authors.forename: Shu-hong
authors.initials: SH
authors.lastname: Yi
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Jun-feng
authors.initials: JF
authors.lastname: Zhang
authors.forename: Hui-min
authors.initials: HM
authors.lastname: Yi
authors.forename: Ying-cai
authors.initials: YC
authors.lastname: Zhang
authors.forename: Gui-hua
authors.initials: GH
authors.lastname: Chen
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D024882:Drug Resistance, Viral; D006509:Hepatitis B / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D063065:Organophosphonates / Q000627:therapeutic use; D012008:Recurrence